With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...

The Alzheimer's disease drug Kisunla will face major reimbursement challenges in the U.K. after the cost-effectiveness watchdog, NICE, said the drug isn't cost-effective.

Researchers at Texas A&M University have developed a nasal spray shown to delay disease progression in animals -- fueling ...

Alzheimer’s trials face the unique challenge of studying participants with cognitive decline, amid a move towards digital ...

The new Alzheimer’s drug Kisunla has been approved in the UK, but the government won’t be paying for it after an independent ...

A slow launch for Alzheimer's medicine Leqembi, a lackluster pipeline and a challenging drug launch environment are just a ...

Britain’s drug regulator approved the Alzheimer’s drug Kisunla on Wednesday, but the government won’t be paying for it after an independent watchdog agency said the treatment isn’t worth the cost to t ...

November is Alzheimer's Awareness Month and 7 News met Grand Island couple Tom and Michele Drabik, who shared their ...

A modified dosing regimen with Eli Lilly’s Alzheimer’s drug Kisunla (donanemab) has shown a reduction in amyloid-related imaging abnormalities with oedema/effusion (ARIA-E). Lilly announced ...

LONDON (AP) — Britain’s drug regulator approved the Alzheimer’s drug Kisunla on Wednesday, but the government won’t be paying for it after an independent watchdog agency said the treatment ...